Abbott Laboratories (ABT) : Foster Dykema Cabot Co Incma reduced its stake in Abbott Laboratories by 4.27% during the most recent quarter end. The investment management company now holds a total of 12,330 shares of Abbott Laboratories which is valued at $555,343 after selling 550 shares in Abbott Laboratories , the firm said in a disclosure report filed with the SEC on Aug 11, 2016.Abbott Laboratories makes up approximately 0.13% of Foster Dykema Cabot Co Incma’s portfolio.
Other Hedge Funds, Including , United Services Automobile Association boosted its stake in ABT in the latest quarter, The investment management firm added 22,831 additional shares and now holds a total of 613,401 shares of Abbott Laboratories which is valued at $27,627,581. Abbott Laboratories makes up approx 0.09% of United Services Automobile Association’s portfolio.Parkside Financial Bank Trust reduced its stake in ABT by selling 1,499 shares or 12.15% in the most recent quarter. The Hedge Fund company now holds 10,840 shares of ABT which is valued at $487,258. Abbott Laboratories makes up approx 0.23% of Parkside Financial Bank Trust’s portfolio.Advisory Services Network boosted its stake in ABT in the latest quarter, The investment management firm added 2,722 additional shares and now holds a total of 4,957 shares of Abbott Laboratories which is valued at $216,472. Abbott Laboratories makes up approx 0.05% of Advisory Services Network’s portfolio.Redwood Investments reduced its stake in ABT by selling 38 shares or 27.14% in the most recent quarter. The Hedge Fund company now holds 102 shares of ABT which is valued at $4,454.
Abbott Laboratories closed down -0.27 points or -0.61% at $43.9 with 74,01,381 shares getting traded on Tuesday. Post opening the session at $44.37, the shares hit an intraday low of $43.9 and an intraday high of $44.42 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.
Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.